Breaking through the complexity of living with type 2 diabetes*1-10
%20rev.png)
.png)
.png)
RCT: Randomized controlled trial RWE: Real-world evidence, Soliqua® is iGlarLixi: insulin glargine 100 U/mL and lixisenatid; ITC: Indirect Treatment Comparison; PSM: Propensity Score Matching.
-
Aroda VR, et al. Diabetes Care. 2016;39:1972–1980.
-
Frias J, et al. Diabetes Obes Metab. 2018;20:2314–8.
-
Blonde L, et al. Diabetes Care. 2021 Mar;44(3):774-780.
-
Rosenstock J, et al. Diabetes Care. 2021;44(10):2361-2370.
-
Home PD, et al. Diabetes Obes Metab. 2021;23(12):2660-2669. doi:10.1111/dom.14518
-
Freemantle N, et al. Diabetes Obes Metab. 2013;15(12):1120-1127. doi:10.1111/dom.12147
-
Pantalone KM, et al. Diabetes. 2022;71(Supplement_1):733-P.
-
Hassanein M, et al. Endocr Soc. 2021;5(Suppl 1):A334. Published 2021 May 3. doi:10.1210/jendso/bvab048.681
-
Tabak AG, et al. Diabetes Ther 2020; 11:305–318.